Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01281865 · ClinicalTrials.gov registry record · Phase 1
Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01281865: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01281865 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01281865, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This phase I/II clinical trial is studying the side effects and best dose of everolimus when given with imatinib mesylate and to see how well they work in treating patients with locally advanced, locally recurrent or metastatic soft tissue sarcoma. Everolimus and imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG imatinib mesylate
- DRUG everolimus
- OTHER diagnostic laboratory biomarker analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-01 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01281865
The ClinicalTrials.gov registry entry for NCT01281865 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which imatinib mesylate is the first listed.
NCT01281865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01281865 about?
NCT01281865 is a clinical study titled "Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma". This phase I/II clinical trial is studying the side effects and best dose of everolimus when given with imatinib mesylate and to see how well they work in treating patients with locally advanced, locally recurrent or metastatic soft tissue sarcoma. Everolimus and imatinib mesylate may stop the growt...
What is the current status of trial NCT01281865?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2011-01. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01281865?
The interventions under investigation include: imatinib mesylate (DRUG), everolimus (DRUG), diagnostic laboratory biomarker analysis (OTHER).
Who is sponsoring clinical trial NCT01281865?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.